Trial reportEBioMedicine2017
Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies.
Trial report in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02845973 (Study of Fecal Bacteria in Early Diagnosis of Colorectal Cancer), which is not on this map. Cited by 109 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Fecal Bacteria in Early Diagnosis of Colorectal Cancer
Who cites it
109 citing papers in PubMed, 6 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Impact of Gut Microbiota on the Clinical Course and Treatment Outcomes of Colorectal Cancer-A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Cross-cohort analysis identifies shared gut microbial signatures and validates microbial risk scores for colorectal cancer.Journal of translational medicine · 2025Pooled it
- Fusobacterium Nucleatum Is a Risk Factor for Metastatic Colorectal Cancer.Current medical science · 2022Pooled it
- Detection of Fusobaterium nucleatum in feces and colorectal mucosa as a risk factor for colorectal cancer: a systematic review and meta-analysis.Systematic reviews · 2020Pooled it
- Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2020Pooled it
- Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta-analysis.Cancer medicine · 2019Pooled it
- Alcohol consumption and colorectal carcinogenesis: an exploration of the gut microbial pathway as a potential mediator.European journal of nutrition · 2026Trial
- Multiomic Analysis of the Gut Microbiome and Serum Metabolome in Response to a Low-Carbohydrate, High-Protein Diet in Individuals With Spinal Cord Injury.Topics in spinal cord injury rehabilitation · 2025Trial
- metaFun: An analysis pipeline for metagenomic big data with fast and unified functional searches.Gut microbes · 2026Article
- Microbiome functional gene pathways are indicative of cognitive performance in older adults at risk for Alzheimer's disease.Gut microbes · 2026Article
- Gut Microbial Topology and Metabolic Signatures Associated With Colorectal Neoplasia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Higher abundance ofmSystems · 2026Article
- Microbiome signatures for detection of colorectal lesions in population-based FIT screening.Nature communications · 2026Article
- Microbiomics: Novel Biomarkers of Colorectal Cancer Diagnosis and Prognosis.Diagnostics (Basel, Switzerland) · 2026Review
- FecalInternational journal of molecular sciences · 2026Article
- Modifications of microbiome-derived cell-free RNA in plasma discriminates colorectal cancer samples.Nature biotechnology · 2026Article
- Article
- Assessment of genome evolution inmSystems · 2026Article
- The relationship between gut microbiota, lifestyle habits, and early-onset colorectal cancer: shedding light on early prediction.British journal of cancer · 2026Observational
- Virulome over taxonomy: refining the driver-passenger model in colorectal carcinogenesis.Frontiers in cellular and infection microbiology · 2026Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedCorrigendum to "Fecal Clostridium Symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies" [Ebiomedicine 25 (2017) 32-40].2018 · Sun, Xiao-Ming [corrected to Sun, Xiao-Min]
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrent non-invasive early detection of colorectal cancer (CRC) requires improvement. We aimed to identified a fecal Clostridium symbiosum-based biomarker for early and advanced colorectal cancer detection.
designIn the test stage, the relative abundance of Clostridium symbiosum (C. symbiosum) was measured by qPCR in 781 cases including 242 controls, 212 colorectal adenoma (CRA) patients, 109 early CRC (tumor restricted to the submucosa) patients, 218 advanced CRC patients. The prediction accuracy was compared to Fusobacterium nucleatum (F. nucleatum), fecal immunochemical test (FIT) and CEA (carcinoembryonic antigen) and validated in an independent cohort of 256 subjects. Current status of the trial:ongoing/still enrolling. Primary endpoint:June, 2017 (Clinicaltrials.gov Identifier NCT02845973).
resultsSignificant stepwise increase of C. symbiosum abundance was found in CRA, early CRC and advanced CRC (P<0.01). C. symbiosum outperformed all the other markers in early CRC prediction performance. The combination of C. symbiosum and FIT achieved better performance (0.803 for test cohort and 0.707 for validation cohort). For overall discrimination of CRCs, the combination of all above markers achieved the performance of 0.876.
conclusionsFecal C. symbiosum is a promising biomarker for early and noninvasive detection of colorectal cancer, being more effective than F. nucleatum, FIT and CEA. Combining C. symbiosum and FIT or CEA may improve the diagnosis power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.